KM12 cell line (KM12)

KM12 is a human colorectal cancer cell line originally established from a patient with Duke's stage B2 colorectal carcinoma (Morikawa et al., 1988, Cancer Res). It is not a therapeutic target molecule but rather a biological model widely used in oncology research and drug screening, notably as part of the NCI-60 human tumor cell line panel (Shoemaker, 2006, Nat Rev Cancer). The cell line is scientifically significant because it harbors a somatic TPM3-NTRK1 gene fusion, which results in the constitutive activation of the TRKA receptor tyrosine kinase (Vaishnavi et al., 2013, Nat Med). This genetic driver makes KM12 cells highly sensitive to tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib and entrectinib, serving as a primary preclinical model for validating these therapies (Ardini et al., 2014, Mol Oncol). Various sublines, such as KM12L4 and KM12SM, have been developed to study different aspects of tumor progression and organ-specific metastasis, particularly to the liver (Cunningham et al., 2020, Scientific Reports). Consequently, while KM12 is a tool for research rather than a drug target, it is essential for understanding the pharmacology of NTRK-targeted agents.

Other names

KM12CKM12L4KM12SMKM-12

Not applicable (KM12 is a cell line, not a molecular target; however, it is used to study drugs that inhibit the TPM3-NTRK1 fusion protein).